Clinical Trial Update: Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 trial evaluated adding bevacizumab to standard chemotherapy for advanced, metastatic, or recurrent non-small cell lung cancer; the trial status is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Lung
• Bronchioloalveolar Carcinoma of the Lung
• Large Cell Lung Cancer
• Non-small Cell Lung Cancer
• Stage Iiib Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer | Phase 2, Phase 3 | Status: COMPLETED